The Effect of Recombinant Human Growth Hormone Combined with Leuprorelin Acetate on Central Precocious Puberty Girls
Objective To explore the clinical effect of recombinant human growth hormone combined with leuprorelin acetate on sexual development abnormalities and bone metabolism in girls with central precocious puberty.Methods From February 2021 to October 2023,89 girls with central precocious puberty treated in the 83rd Group Army Hospital of PLA were selected for the study and randomly divided into a control group and an observation group.The control group of 44 children was treated with leuprorelin acetate,and the observation group of 45 children was treated with recombinant human growth hormone combined with leuprorelin acetate.After 6 months of treatment,the clinical efficacy and safety during treatment of the two groups of children were evaluated,and the changes in sex hormone levels,secondary sexual characteristics,growth and development,and bone metabolism indicators before and after treatment were compared.Results After treatment,the effective rate of treatment in the observation group was significantly better than that in the control group,and the difference was statistically significant(P＜0.05).Before treatment,there was no statistical significance in the comparison of sex hormones,secondary sexual characteristics,and bone metabolism indicators between the two groups(P＞0.05);after treatment,the levels of luteinizing hormone(LH),follicle-stimulating hormone(FSH),estradiol(E2),various indicators of secondary sexual characteristics(breast volume,uterine volume,average ovarian volume,maximum follicle diameter),and bone metabolism indicators[serum osteocalcin(OST),N-terminal mid-fragment(N-MID),Type Ⅰ procollagen N-terminal peptide(PINP)]in both groups were significantly reduced,among which the observation group was significantly lower than the control group,and the difference was statistically significant(P＜0.05).The height difference before and after treatment and the estimated adult height of the children in the observation group were significantly higher than those in the control group,and the difference was statistically significant(P＜0.05).There was no statistical significance in the comparison of bone age between the two groups of children(P＞0.05).During the treatment period,there was no statistical significance in the comparison of the incidence of adverse reactions between the two groups of children(P＞0.05).Conclusion The treatment of girls with central precocious puberty with recombinant human growth hormone combined with leuprorelin acetate can effectively improve the symptoms of the children,inhibit the abnormal development of secondary sexual characteristics and correct the level of bone metabolism,and the application effect is ideal.
central precocious pubertypediatricsrecombinant human growth hormoneleuprorelin acetatesexual development abnormalitiesbone metabolism
万方数据
维普
